PE20210156A1 - Compuestos moduladores de sting y metodos de elaboracion y uso - Google Patents
Compuestos moduladores de sting y metodos de elaboracion y usoInfo
- Publication number
- PE20210156A1 PE20210156A1 PE2020000488A PE2020000488A PE20210156A1 PE 20210156 A1 PE20210156 A1 PE 20210156A1 PE 2020000488 A PE2020000488 A PE 2020000488A PE 2020000488 A PE2020000488 A PE 2020000488A PE 20210156 A1 PE20210156 A1 PE 20210156A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- methods
- fluoro
- preparation
- modulating compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a compuestos que pueden ser utiles como moduladores/agonistas de STING (estimulador de los genes del interferon), metodos de sintesis y metodos de uso para la profilaxis o el tratamiento del cancer y otras enfermedades. Estos compuestos presentan la formula de la Figura 1 o una sal farmaceuticamente aceptable, en donde: X1 es SH u OH; X2 es SH u OH; Ya es O, S, o CH2; Yb es O, S, -NH, o NRa; R1 es hidrogeno, fluoro, OH, NH2, ORb, o NHRb; R2 es hidrogeno o fluoro; R3 es hidrogeno; R4 es hidrogeno, fluoro, OH, NH2, ORb, o NHRb; o R3 y R4 se toman juntos para formar CH2O; R5 es hidrogeno o fluoro; el anillo A y el anillo B son como se indica en el texto de la reivindicacion.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762584559P | 2017-11-10 | 2017-11-10 | |
US201862718613P | 2018-08-14 | 2018-08-14 | |
US201862754623P | 2018-11-02 | 2018-11-02 | |
PCT/IB2018/058846 WO2019092660A1 (en) | 2017-11-10 | 2018-11-09 | Sting modulator compounds, and methods of making and using |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210156A1 true PE20210156A1 (es) | 2021-01-26 |
Family
ID=64604678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000488A PE20210156A1 (es) | 2017-11-10 | 2018-11-09 | Compuestos moduladores de sting y metodos de elaboracion y uso |
Country Status (17)
Country | Link |
---|---|
US (1) | US11542293B2 (es) |
EP (1) | EP3707151B1 (es) |
JP (1) | JP7195317B2 (es) |
KR (1) | KR20200098511A (es) |
CN (1) | CN111566119A (es) |
AU (1) | AU2018364708A1 (es) |
BR (1) | BR112020009126A2 (es) |
CA (1) | CA3082351A1 (es) |
CL (1) | CL2020001234A1 (es) |
CO (1) | CO2020006523A2 (es) |
EC (1) | ECSP20029790A (es) |
IL (1) | IL274570A (es) |
MX (1) | MX2020004858A (es) |
PE (1) | PE20210156A1 (es) |
SG (1) | SG11202004113VA (es) |
TW (1) | TW201922263A (es) |
WO (1) | WO2019092660A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US10519187B2 (en) * | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
CN111954675A (zh) | 2018-04-06 | 2020-11-17 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸 |
US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
AU2022361238A1 (en) * | 2021-10-05 | 2024-04-11 | Sanegene Bio Usa Inc. | Polyhydroxylated cyclopentane derivatives and methods of use |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
JPWO2005005450A1 (ja) | 2003-07-15 | 2006-08-24 | 三井化学株式会社 | 環状ビスジヌクレオチドの合成方法 |
WO2005030186A2 (en) | 2003-07-28 | 2005-04-07 | Univ Maryland | Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
US7709458B2 (en) | 2004-03-15 | 2010-05-04 | David K. R. Karaolis | Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
WO2006045041A2 (en) | 2004-10-18 | 2006-04-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for microbial biofilm destruction and interference with microbial cellular physiology |
EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
WO2011003025A1 (en) | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック,インコーポレイテッド | 癌免疫療法のための組成物および方法 |
US9090646B2 (en) | 2012-12-05 | 2015-07-28 | Rutgers, The State University Of New Jersey | Biotinylated compounds |
SI2931738T1 (sl) | 2012-12-13 | 2019-05-31 | Aduro Biotech, Inc. | Sestave, ki vsebujejo ciklične purin dinukleotide z definirano stereokemijo, ter metode za njihovo pripravo in uporabo |
BR112015014462A2 (pt) | 2012-12-19 | 2017-07-11 | Univ Texas | vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos |
JP6153116B2 (ja) | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
AU2014260015B2 (en) | 2013-04-29 | 2019-11-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック,インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
EP3071229A4 (en) | 2013-11-22 | 2017-05-10 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
MX2016015928A (es) * | 2014-06-04 | 2017-03-20 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting. |
PT3233882T (pt) | 2014-12-16 | 2020-01-21 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para a indução de citocinas |
WO2016096577A1 (en) | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
BR112017018908A2 (pt) | 2015-03-10 | 2018-04-17 | Aduro Biotech, Inc. | composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon |
WO2017011444A1 (en) | 2015-07-13 | 2017-01-19 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating b cell cancers |
WO2017011622A1 (en) | 2015-07-14 | 2017-01-19 | Spring Bank Pharmaceuticals, Inc. | Compounds and compositions that induce rig-i-and other pattern recongnition receptors |
CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
US10738074B2 (en) | 2015-08-13 | 2020-08-11 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as STING agonists |
MX2018005299A (es) | 2015-10-28 | 2019-03-18 | Aduro Biotech Inc | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon". |
US20170146519A1 (en) | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
KR101949108B1 (ko) | 2015-12-03 | 2019-02-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Sting의 조정제로서의 시클릭 푸린 디뉴클레오티드 |
DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
US20180369268A1 (en) | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
EA036421B1 (ru) | 2016-01-11 | 2020-11-09 | Иннэйт Тьюмор Иммьюнити, Инк. | Соединения и композиции для лечения состояний, ассоциированных с активностью sting |
US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
PT3429596T (pt) * | 2016-03-18 | 2022-11-25 | Immune Sensor Llc | Compostos de dinucleotídeos cíclicos e métodos de utilização |
EP3432868B1 (en) | 2016-03-23 | 2020-12-16 | Academia Sinica | Thin-shell polymeric nanoparticles and uses thereof |
CN109563081A (zh) | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
EP3481402A4 (en) | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE |
TW201803886A (zh) | 2016-07-06 | 2018-02-01 | 史貝羅威生物科學有限公司 | 化合物、組合物及用於治療疾病之方法 |
WO2018013887A1 (en) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
SG11201900154VA (en) | 2016-07-15 | 2019-02-27 | Sperovie Biosciences Inc | Compounds, compositions, and methods for the treatment of disease |
US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
SI3523287T1 (sl) | 2016-10-04 | 2021-11-30 | Merck Sharp & Dohme Corp. | Benzo(b)tiofenske spojine kot agonisti STING |
EP3523314A1 (de) | 2016-10-07 | 2019-08-14 | Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH | Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen |
JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
CA3047113A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
RU2019122602A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака |
WO2018119117A1 (en) | 2016-12-22 | 2018-06-28 | The Regents Of The University Of California | Methods of producing cyclic dinucleotides |
ES2891326T3 (es) | 2017-01-27 | 2022-01-27 | Janssen Biotech Inc | Dinucleótidos cíclicos como agonistas de la STING |
CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
WO2018138685A2 (en) | 2017-01-27 | 2018-08-02 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
WO2018156625A1 (en) | 2017-02-21 | 2018-08-30 | Board Of Regents,The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
CN106667914B (zh) | 2017-03-13 | 2022-02-01 | 杭州星鳌生物科技有限公司 | 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用 |
JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP3692048A4 (en) | 2017-08-30 | 2021-10-20 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
WO2019046496A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
US10953032B2 (en) | 2017-08-31 | 2021-03-23 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
CN111212839A (zh) | 2017-09-15 | 2020-05-29 | 艾杜罗生物科技公司 | 吡唑并嘧啶酮化合物及其用途 |
JP7337086B2 (ja) | 2018-03-23 | 2023-09-01 | 武田薬品工業株式会社 | スルファメート結合を有するstingモジュレーター化合物、及び製造及び使用の方法 |
JP2022540605A (ja) | 2019-07-09 | 2022-09-16 | 武田薬品工業株式会社 | Stingアゴニスト及びチェックポイント阻害剤の投与 |
-
2018
- 2018-11-09 JP JP2020526002A patent/JP7195317B2/ja active Active
- 2018-11-09 US US16/762,710 patent/US11542293B2/en active Active
- 2018-11-09 WO PCT/IB2018/058846 patent/WO2019092660A1/en unknown
- 2018-11-09 AU AU2018364708A patent/AU2018364708A1/en not_active Abandoned
- 2018-11-09 CA CA3082351A patent/CA3082351A1/en active Pending
- 2018-11-09 PE PE2020000488A patent/PE20210156A1/es unknown
- 2018-11-09 KR KR1020207016227A patent/KR20200098511A/ko not_active Application Discontinuation
- 2018-11-09 EP EP18814686.4A patent/EP3707151B1/en active Active
- 2018-11-09 BR BR112020009126-0A patent/BR112020009126A2/pt not_active Application Discontinuation
- 2018-11-09 TW TW107139917A patent/TW201922263A/zh unknown
- 2018-11-09 MX MX2020004858A patent/MX2020004858A/es unknown
- 2018-11-09 CN CN201880073336.7A patent/CN111566119A/zh active Pending
- 2018-11-09 SG SG11202004113VA patent/SG11202004113VA/en unknown
-
2020
- 2020-05-08 CL CL2020001234A patent/CL2020001234A1/es unknown
- 2020-05-10 IL IL274570A patent/IL274570A/en unknown
- 2020-05-28 CO CONC2020/0006523A patent/CO2020006523A2/es unknown
- 2020-06-08 EC ECSENADI202029790A patent/ECSP20029790A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3707151B1 (en) | 2022-01-05 |
JP2021502383A (ja) | 2021-01-28 |
IL274570A (en) | 2020-06-30 |
CN111566119A (zh) | 2020-08-21 |
ECSP20029790A (es) | 2020-09-30 |
US20210171565A1 (en) | 2021-06-10 |
AU2018364708A1 (en) | 2020-05-21 |
JP7195317B2 (ja) | 2022-12-23 |
US11542293B2 (en) | 2023-01-03 |
KR20200098511A (ko) | 2020-08-20 |
BR112020009126A2 (pt) | 2020-10-20 |
TW201922263A (zh) | 2019-06-16 |
CA3082351A1 (en) | 2019-05-16 |
CO2020006523A2 (es) | 2020-08-21 |
CL2020001234A1 (es) | 2020-12-04 |
WO2019092660A1 (en) | 2019-05-16 |
MX2020004858A (es) | 2020-10-01 |
SG11202004113VA (en) | 2020-06-29 |
EP3707151A1 (en) | 2020-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210156A1 (es) | Compuestos moduladores de sting y metodos de elaboracion y uso | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
PE20181297A1 (es) | Dinucleotidos de purino ciclico como moduladores de sting | |
DOP2016000316A (es) | Dinucleótidos cíclicos como moduladores de sting | |
CO2017013432A2 (es) | Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones | |
ECSP18087352A (es) | Formulaciones de un inhibidor de lsd1 | |
UY37461A (es) | 1,2,4 – triazolonas 2,4,5 trisustituida | |
CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
PE20181345A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer | |
CO6870032A2 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
CL2020002352A1 (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
CL2019002220A1 (es) | Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos. | |
CU20170007A7 (es) | Compuestos de imidazopiridazina | |
CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
DOP2019000228A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
CO2019003894A2 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
PE20180599A1 (es) | Construcciones de calicheamicina y sus metodos de uso | |
CR20170466A (es) | Material de implante compuesto | |
CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
CL2023001816A1 (es) | Parapoxvirus modificado que tiene inmunogenicidad incrementada | |
CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
EA202091743A1 (ru) | Вакцинация дендритными клетками параллельно с химиотерапией |